Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Analyst consensus is “Moderate Buy”: Six of nine analysts recommend buying Zenas BioPharma, while two rate it a hold and one a sell. The average 12-month price target is $45.71, above the reported $32.32 share price.
• Quarterly results fell short of expectations: Zenas reported a loss of $1.77 per share versus the $1.12 consensus estimate, while revenue totaled $1 million compared with analysts’ $15 million forecast.
• The clinical-stage biotech remains volatile: ZBIO has traded between $13.50 and $44.60 over the past year, and several institutional investors recently initiated or increased positions. The company is developing obexelimab for immune-mediated diseases including lupus and IgG4-related disease.

Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) has received an average rating of "Moderate Buy" from the nine research firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $45.7143.

A number of equities analysts have recently commented on the stock. Morgan Stanley lifted their price target on shares of Zenas BioPharma from $22.00 to $32.00 and gave the company an "equal weight" rating in a research report on Friday, August 14th. Citigroup reaffirmed a "buy" rating on shares of Zenas BioPharma in a report on Wednesday, June 3rd. HC Wainwright reiterated a "buy" rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Wall Street Zen upgraded shares of Zenas BioPharma from a "strong sell" rating to a "sell" rating in a report on Saturday, June 27th. Finally, Weiss Ratings lowered shares of Zenas BioPharma from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Thursday, July 9th.

Hedge Funds Weigh In On Zenas BioPharma

A number of institutional investors have recently made changes to their positions in the business. Quantbot Technologies LP bought a new stake in Zenas BioPharma in the 2nd quarter valued at $49,000. ProShare Advisors LLC bought a new position in shares of Zenas BioPharma during the 4th quarter worth about $211,000. Jupiter Topco LLC bought a new position in shares of Zenas BioPharma during the 2nd quarter worth about $201,000. The Manufacturers Life Insurance Company acquired a new position in shares of Zenas BioPharma during the second quarter valued at about $204,000. Finally, Bank of New York Mellon Corp raised its position in shares of Zenas BioPharma by 17.5% during the first quarter. Bank of New York Mellon Corp now owns 60,864 shares of the company's stock valued at $1,190,000 after buying an additional 9,062 shares during the last quarter.

Zenas BioPharma Stock Performance

ZBIO opened at $32.32 on Thursday. The company has a market cap of $2.11 billion, a PE ratio of -3.60 and a beta of -1.04. The stock has a 50-day moving average of $31.42 and a 200-day moving average of $24.82. Zenas BioPharma has a 52-week low of $13.50 and a 52-week high of $44.60. The company has a debt-to-equity ratio of 1.57, a quick ratio of 9.93 and a current ratio of 9.93.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($1.77) earnings per share for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.65). The company had revenue of $1.00 million during the quarter, compared to analyst estimates of $15.00 million. As a group, equities research analysts forecast that Zenas BioPharma will post -5.81 earnings per share for the current fiscal year.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for patients with immune-mediated diseases. The company's research and development efforts are centered on therapies that modulate the immune system and address conditions with significant unmet medical needs.

Zenas' lead investigational product is obexelimab, an immune-modulating monoclonal antibody designed to inhibit the activity of certain B cells without broadly depleting them. The company is evaluating obexelimab in autoimmune and inflammatory diseases, including IgG4-related disease and systemic lupus erythematosus.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.